A Phase II Study of Docetaxel and Oxaliplatin for Second-Line Treatment of Urothelial Carcinoma

Publisher： Karger

E-ISSN： 1421-9794|55|5|321-326

ISSN： 0009-3157

Source： Chemotherapy, Vol.55, Iss.5, 2009-07, pp. : 321-326

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of Docetaxel as a Second-Line Chemotherapy for Thymic Carcinoma

By  

Chemotherapy, Vol. 50, Iss. 6, 2004-12 ,pp. : 279-282

Karger

Access to resources Recommend Favorite

Phase II Study of Biweekly Plitidepsin as Second-Line Therapy for Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium

By Dumez Herlinde   Gallardo Enrique   Culine Stephane   Galceran Joan Carles   Schöffski Patrick   Droz Jean P.   Extremera Sonia   Szyldergemajn Sergio   Fléchon Aude  

Marine Drugs, Vol. 7, Iss. 3, 2009-09 ,pp. : 451-463

MDPI

Access to resources Recommend Favorite

Combination Chemotherapy with Irinotecan and Ifosfamide as Second-Line Treatment of Refractory or Sensitive Relapsed Small Cell Lung Cancer: A Phase II Study

By  

Chemotherapy, Vol. 49, Iss. 4, 2003-07 ,pp. : 200-205

Karger

Access to resources Recommend Favorite

Phase I/II Trial of Irinotecan and S-1 Combination Chemotherapy as a Second-Line Treatment for Advanced Colorectal Cancer

By  

Chemotherapy, Vol. 59, Iss. 5, 2014-05 ,pp. : 338-343

Karger

Access to resources Recommend Favorite

Hepatic Arterial Infusion of Gemcitabine plus Oxaliplatin as Second-Line Treatment for Locally Advanced Intrahepatic Cholangiocarcinoma: Preliminary Experience

By  

Chemotherapy, Vol. 59, Iss. 5, 2014-05 ,pp. : 354-360

Karger

Access to resources Recommend Favorite